Int J Surg Case Rep:肾细胞癌来源的甲状腺癌一例

2014-12-04 MedSci MedSci原创

Int J Surg Case Rep:肾细胞癌来源的甲状腺癌一例 这是来自伊朗的一篇病例报告:一58岁男性因发现快速生长的左侧颈部肿物伴随疼痛3月就诊,追问病史得知1.5年前曾因低分化肾细胞癌(RCC)行左肾切除术,临床分期为T1bN2M0,体检触及甲状腺左叶8*6cm肿块,查甲状腺功能在正常范围,颈部超声提示甲状腺左叶9*7cm低回声结节,无微钙化及囊性成分,腹部超声提示肝左右叶多发低回

这是来自伊朗的一篇病例报告:一58岁男性因发现快速生长的左侧颈部肿物伴随疼痛3月就诊,追问病史得知1.5年前曾因低分化肾细胞癌(RCC)行左肾切除术,临床分期为T1bN2M0,体检触及甲状腺左叶8*6cm肿块,查甲状腺功能在正常范围,颈部超声提示甲状腺左叶9*7cm低回声结节,无微钙化及囊性成分,腹部超声提示肝左右叶多发低回声圆形结节(1-3cm),细针穿刺细胞学提示单层恶性腺细胞,伴颗粒细胞质,呈多形核,核内有假包涵体,复合肾细胞癌转移。

肾细胞癌来源的甲状腺转移在临床上实属罕见,原因在于甲状腺含高碘、高氧含量、高速血流,因此可有效防止肿瘤细胞定植,但是上述环境遭到破坏(比如甲状腺肿或甲状腺炎)。甲状腺就会受到转移肿瘤的侵袭

以往的研究提示肾细胞癌在术后20年都有可能转移至甲状腺,细针穿刺细胞学检查对于检查甲状腺转移癌有很高的灵敏度和特异度,外科切除甲状腺转移癌并不能提高中位生存率,因此临床医生要详细询问病史,遇到此类情况要考虑是否有恶性肿瘤病史,准确诊断。

原文出处:

Mohammadi, A., S.B. Toomatari, and M. Ghasemi-Rad, Metastasis from renal cell carcinoma to thyroid presenting as rapidly growing neck mass. Int J Surg Case Rep, 2014. 5(12): p. 1110-1112.

本文是MedSci原创编译整理,欢迎转载!转载请注明来源并附原文链接。谢谢!

您还可以这样阅读,更多资讯,请关注MedSci微信
   

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=72496, encodeId=6f70e249653, content=着。。。神奇, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Tue Mar 22 00:08:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027915, encodeId=2ddf202e91581, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Fri May 08 11:42:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978401, encodeId=8b1319e840148, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Oct 18 23:42:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624731, encodeId=94b61624e31ad, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Sat Dec 06 11:42:00 CST 2014, time=2014-12-06, status=1, ipAttribution=)]
    2016-03-22 Gsurgeon

    着。。。神奇

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=72496, encodeId=6f70e249653, content=着。。。神奇, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Tue Mar 22 00:08:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027915, encodeId=2ddf202e91581, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Fri May 08 11:42:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978401, encodeId=8b1319e840148, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Oct 18 23:42:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624731, encodeId=94b61624e31ad, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Sat Dec 06 11:42:00 CST 2014, time=2014-12-06, status=1, ipAttribution=)]
    2015-05-08 charl1234567
  3. [GetPortalCommentsPageByObjectIdResponse(id=72496, encodeId=6f70e249653, content=着。。。神奇, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Tue Mar 22 00:08:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027915, encodeId=2ddf202e91581, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Fri May 08 11:42:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978401, encodeId=8b1319e840148, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Oct 18 23:42:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624731, encodeId=94b61624e31ad, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Sat Dec 06 11:42:00 CST 2014, time=2014-12-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=72496, encodeId=6f70e249653, content=着。。。神奇, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Tue Mar 22 00:08:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027915, encodeId=2ddf202e91581, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Fri May 08 11:42:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978401, encodeId=8b1319e840148, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Oct 18 23:42:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624731, encodeId=94b61624e31ad, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Sat Dec 06 11:42:00 CST 2014, time=2014-12-06, status=1, ipAttribution=)]
    2014-12-06 yaanren

相关资讯

Ann Surg:甲状腺球蛋白或为甲状腺癌预后因素

乳头状甲状腺癌(PTC)患者手术及放射治疗后血清甲状腺球蛋白(Tg)水平降至不可探测水平(<1.0 ng/mL)与低复发率及生化缓解相关。 密歇根大学外科系Hughes博士等进行了一项临床研究,旨在确定总甲状腺切除术及中央区或颈侧淋巴结清扫术对区域性晚期(T1-4bN1bM0)乳头状甲状腺癌的有效性及对治疗后甲状腺球蛋白水平的影响。研究结果于2014年1月在线发表于《外科肿瘤学年鉴》杂

lenvatinib用于甲状腺癌获得良好的疗效(SELECT研究)

Lenvatinib是一种口服多受体酪氨酸激酶(RTK)抑制剂,具有新颖的结合模式,除抑制参与肿瘤增殖的其他促血管生成和致癌信号通路相关RTK外,还能够选择性抑制血管内皮生长因子(VEGF)受体的激酶活性。目前,卫材也正在评估lenvatinib用于其他癌症的治疗。Lenvatinib在日本、美国、欧盟提交的申请文件,是基于III期SELECT研究的积极顶线数据。该研究是一项多中心、随机、双盲、安

CSMO 2014:林岩松谈分化型甲状腺癌手术后放射性碘-131治疗的规范

在7月4日的第八届中国肿瘤内科大会会上,北京协和医院核医学科的林岩松教授介绍分化型甲状腺癌手术后放射性碘-131治疗的规范。甲状腺癌是最常见的内分泌系统恶性肿瘤,占全身恶性肿瘤的1.1%(男性约0.5%,女性约2.0%)。发病率逐年增高以其日益引人关注。目前甲状腺癌发病率已列入恶性肿瘤前十位,女性恶性肿瘤中位于第八位。多数甲状腺癌的预后较好,死亡率低,但随处置不同其复发率亦不同,复发不仅影响患者的

Cell:甲状腺癌基因组分析或可帮助寻找恶性肿瘤标记物

近日,来自美国密歇根大学医学院的研究人员通过对甲状腺癌进行研究鉴别出了恶性肿瘤的标记物,其或许可以帮助开发治疗癌症的个体化靶向疗法,相关研究刊登于国际杂志Cell上。 文章中,研究者Thomas J. Giordano表示,对甲状腺癌基因组蓝图的理解将会进一步帮助其进行精确分类及改善分子诊断技术,同时也可以帮助我们分离出那些需要进行积极治疗的病人。甲状腺癌的发病率在过去30年增加了3倍,而且

Lancet Diab & Endo:放射性碘抵抗分化型甲状腺癌的定义和管理

针对转移分化型甲状腺癌,放射性碘(131I)治疗可以根除肿瘤细胞,且效果明显。然而,即使予以足量的促甲状腺激素刺激,同时避免过量碘摄入,仅2/3转移分化型甲状腺癌患者可摄入大量碘,治愈率仅42%。放射碘治疗无效的患者预期生存3-5年,而且缺少相应药物的治疗。【原文下载】 由于缺乏放射碘抵抗分化型甲状腺癌的诊治共识,治疗一度受阻。为此,专家组于2012年9月就诊断和治疗

TSH可预测10 mm以上分化型甲状腺癌风险

解放军总医院内分泌科;第一作者现在北京市海淀医院闫慧娴、谷伟军和杨国庆等分析了血中促甲状腺激素(TSH)水平与甲状腺乳头状微小癌之间的相关性。结果表明,血清TSH是预测分化型甲状腺癌风险的指标之一,血清TSH可以对直径大于10 mm分化型甲状腺癌的风险进行预测,但它并不是甲状腺乳头状微小癌良好的预测因子。相关论文发表于2014年第8期《中华内分泌代谢杂志》。 研究者们回顾性分析了1999年10月